AIM ImmunoTech (STU:HXB2) Short-Term Debt & Capital Lease Obligation : €1.71 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. AIM ImmunoTech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.71 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. AIM ImmunoTech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.37 Mil.

AIM ImmunoTech Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for AIM ImmunoTech's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Short-Term Debt & Capital Lease Obligation Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

0.23

0.03

0.17

0.20

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															0.17	0.19	0.19	0.20	1.71

AIM ImmunoTech Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

AIM ImmunoTech Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines